In the British Journal of Cancer this week, researchers in Belgium assess the clinicopathological significance of IDO1 expression in colorectal cancer. Because it modulates T-cell response to infection, IDO1 may be co-opted by carcinomas to create an immunosuppressive state, the authors write. In this study, the team investigated IDO1 expression in three colon cancer cell lines, and found that higher IDO1 expression at the tumor invasion site was an adverse prognostic marker.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.